Why Divi's Laboratories Share Price Is Rising Today

The short version

• Divi's Laboratories shares rose 1.01% to Rs 9,242.50 after a European regulatory panel backed Foundayo.
• Analysts expect Divi's to supply intermediates for Eli Lilly's oral weight loss drug, Orforglipron.
• Investors will watch the September quarter results and any updates on the potential supply opportunity.

Divi's Laboratories shares traded higher on October 19 after a European regulatory panel issued a positive opinion on Eli Lilly's oral weight loss drug, Orforglipron, also known as Foundayo. The stock was up 1.01% at Rs 9,242.50 at 10:19 am.

The development has drawn attention to Divi's Laboratories because analysts believe the pharmaceutical company could supply intermediates used in manufacturing the drug. However, the supplied information does not confirm a commercial supply agreement or disclose the potential revenue from such business.

Foundayo has already received approval for weight loss in the United States. Its European regulatory progress and reported sales have brought further attention to the drug's commercial prospects, while Divi's recent financial results provide another factor for investors to assess.

What happened with Foundayo in Europe?

The Committee for Medicinal Products for Human Use (CHMP), a scientific committee of the European Medicines Agency, issued a positive opinion on Orforglipron. Such an opinion is part of the European Union's medicine authorisation process. The supplied information does not specify the final European Commission decision or the date on which a final authorisation may be granted.

Orforglipron is an oral weight loss drug developed by Eli Lilly. Its progress matters to pharmaceutical manufacturers that may supply ingredients or intermediate compounds used in production. Divi's Laboratories has attracted attention because analysts expect it could be an intermediate supplier for the medicine.

That possibility remains an expectation, not a confirmed order. The available information does not disclose the size of any potential supply contract, the volume Divi's could manufacture or the expected contribution to its revenue and profit. Investors will need further company disclosures to establish whether the regulatory progress translates into business for Divi's Laboratories.

Foundayo sales and regulatory timeline

The US Food and Drug Administration (USFDA) approved Foundayo for weight loss on April 1, 2026. The drug recorded $98 million in global sales during the second quarter of 2026, with the United States and the United Arab Emirates accounting for the reported sales.

Particulars	Details
Drug	Orforglipron, marketed as Foundayo
Developer	Eli Lilly
US approval date	April 1, 2026
Global sales in Q2 2026	$98 million
Sales in the United States	$67 million
Sales in the UAE	$31 million
European regulatory development	Positive CHMP opinion

The United States accounted for the larger share of the reported sales, while the UAE contributed the remainder. These figures provide an early indication of commercial activity, but they do not establish how much business Divi's Laboratories could secure.

For a potential supplier, the effect would depend on whether it receives manufacturing orders, the quantities required and the commercial terms. The available information does not provide these details. Foundayo's sales therefore offer context for the drug's progress, rather than a direct estimate of Divi's future revenue.

Divi's Laboratories Q1 FY27 results

Divi's Laboratories reported strong growth in the first quarter of FY27, with consolidated net profit rising 65.6% year on year to Rs 902 crore from Rs 545 crore. Revenue from operations increased 27.8% to Rs 3,080 crore from Rs 2,410 crore in the same quarter a year earlier.

Earnings before interest, taxes, depreciation and amortisation (EBITDA) rose 72.2% to Rs 1,255 crore from Rs 729 crore. Profit and EBITDA grew faster than revenue, indicating that earnings improved at a stronger rate than sales during the quarter.

Financial metric	Q1 FY27	Q1 FY26	Year on year growth
Consolidated net profit	Rs 902 crore	Rs 545 crore	65.6%
Revenue from operations	Rs 3,080 crore	Rs 2,410 crore	27.8%
EBITDA	Rs 1,255 crore	Rs 729 crore	72.2%

Divi's reported profit was also above the estimate of Rs 657 crore cited in the supplied material. Revenue exceeded the estimate of Rs 2,911 crore, while EBITDA was well above the estimate of Rs 915 crore. These comparisons indicate that the company delivered stronger results than the cited forecasts for the quarter.

The figures provide a financial base against which investors can assess subsequent performance. However, the first quarter results do not establish how much, if any, revenue from Orforglipron related supplies may be recognised in future periods.

How did Divi's Laboratories shares perform?

At 10:19 am on October 19, Divi's Laboratories shares were trading at Rs 9,242.50, up 1.01% for the session. The stock's performance over longer periods was mixed, with a decline over the previous month but a substantial gain since the start of the year.

Share price indicator	Performance
Share price at 10:19 am	Rs 9,242.50
Change during the session	+1.01%
Change over one month	−1.8%
Change year to date	+45.7%

The session's gain followed the positive European regulatory opinion on Foundayo and expectations of a possible supply role for Divi's. However, the available information does not establish that the drug development was the sole reason for the share price movement.

The stock's year to date gain also provides a broader reference point. Daily movements, monthly performance and annual returns measure different periods, so they should be assessed separately when reviewing the stock's trading pattern.

Why the potential supply opportunity matters

If Divi's Laboratories supplies intermediates for Orforglipron, the business could add to its pharmaceutical manufacturing activity. The commercial impact would depend on the scale of orders and the terms of any supply arrangement. No confirmed contract value or revenue forecast is available in the supplied information.

Regulatory progress is one part of the process. Actual business depends on further steps, including any final authorisation in Europe, manufacturing requirements and commercial arrangements between the relevant parties. A positive committee opinion alone does not confirm that Divi's will receive orders.

Investors following the pharmaceutical sector can also track developments at other drug manufacturers. WeloMoney has covered developments involving Morepen Laboratories' share price movement and Ind Swift Laboratories' revenue target. These are separate company developments and do not establish any direct connection with Divi's or Foundayo.

What investors should watch

The next developments to monitor are the company's September quarter results and any specific disclosure about its potential role in Orforglipron's supply chain. Divi's Laboratories had not disclosed its September quarter earnings date in the supplied information.

Investors can follow these developments:

• The September quarter results announcement and financial performance.
• Any company confirmation of an intermediate supply arrangement with Eli Lilly.
• Further regulatory developments for Foundayo in Europe.
• Future sales figures for the drug and any disclosed manufacturing requirements.
• Revenue growth, EBITDA and net profit in subsequent quarters.

These factors can help distinguish the drug's commercial progress from the actual financial impact on Divi's Laboratories. Until a supply arrangement or its financial terms are confirmed, the potential business remains an expectation.

Frequently asked questions

Why did Divi's Laboratories shares rise on October 19?

Divi's Laboratories shares rose 1.01% to Rs 9,242.50 at 10:19 am on October 19 after a European regulatory committee issued a positive opinion on Eli Lilly's weight loss drug Foundayo. Analysts expect Divi's could supply intermediates for the drug, although a supply contract was not confirmed in the supplied information.

What is Foundayo and who makes it?

Foundayo is the brand name for Orforglipron, an oral weight loss drug developed by Eli Lilly. The USFDA approved it for weight loss on April 1, 2026. The drug recorded $98 million in global sales in the second quarter of 2026.

How much did Foundayo generate in sales in Q2 2026?

Foundayo generated $98 million in reported global sales in the second quarter of 2026. The United States accounted for $67 million and the UAE contributed $31 million. These figures do not establish the revenue Divi's Laboratories may earn from supplying intermediates.

What were Divi's Laboratories' Q1 FY27 results?

Divi's Laboratories reported consolidated net profit of Rs 902 crore, up 65.6% year on year, in Q1 FY27. Revenue from operations rose 27.8% to Rs 3,080 crore, while EBITDA increased 72.2% to Rs 1,255 crore.

Has Divi's Laboratories confirmed a supply deal for Orforglipron?

The supplied information does not confirm a supply deal between Divi's Laboratories and Eli Lilly for Orforglipron. Analysts expect Divi's could supply intermediates, but the potential contract value, order volumes and revenue contribution have not been disclosed.

When will Divi's Laboratories announce its Q2 FY27 results?

Divi's Laboratories had not disclosed its September quarter earnings date in the supplied information. Investors will need to follow the company's announcement for the confirmed reporting schedule and its latest financial performance.